EUCTR2013-000313-20-FR进行中（未招募）不适用
Evaluation of the biological response to clopidogrel in patients with ischemic stroke: role of platelet alpha2-adrenergic receptors - AAPIX
CHU de Saint-Etienne0 个研究点开始时间: 2014年4月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Consent signed
- •- Patient over 18 years old
- •- Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications
- •- normal standard biological tests
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •- Need to continue aspirin therapy
- •- Patients with a recurrence of clopidogrel AIC
- •- Patient already tacking clopidogrel
- •- Drugs interfering with the adrenergic system alpha blockers, beta blockers, alpha 2 receptor agonists (alpha-methyldopa) and alpha2 receptor inhibitors (Mianserin, Mirtazapine, yohimbine)
- •- Contra indication of clopidogrel and / or any of its excipients
研究者
相似试验
尚未招募
Unknown
Effect of concomitant use of Clopidogrel with IlaprazoleCTRI/2024/05/067704SRM College of Pharmacy, SRM Institute of Science and Technology
已完成
2 期
Comparing the effect of Loading Doses of Clopidogrel and Prasugrel on the incidence of myocardial injury in the Candidates for Elective Percutaneous Coronary InterventioSubsequent myocardial infarction.For morbidity coding, this category should be assigned for infarction of any myocardial site, occurring within 4 weeks (28 days) from onset of a previous infarctionIRCT201408069768N3Tehran University of Medical Sciences90
进行中（未招募）
1 期
Pilot Study related to the effect of clopidogrel on plasmatic soluble CD40 ligand during systemic lupus erythematoussystemic lupus erythematousEUCTR2014-003733-25-FRCHU de BORDEAUX30
进行中（未招募）
不适用
Assessing Platelet Inhibitory Response to Clopidogrel – Feasibility, Safety and Cost Analysis of a Tailored Platelet Inhibition Strategy for Elective PCI Patients - Plavix and PrasugrelTo investigate the feasibility, safety and cost of using the platelet assay VerifyNow-P2Y12 to guide optimal P2Y12 platelet inhibition in patients undergoing elective PCI, compared with standard treatment, at a UK tertiary referral cardiology centre.EUCTR2010-018435-18-GBPapworth Hospital NHS Foundation Trust200
尚未招募
4 期
Does the dual antiplatelet medication of aspirin and either clopidogrel or prasugrel affect inflammatory and oxidative stress measures in individuals with acute coronary syndrome similarly?CTRI/2023/07/055349Pt B D Sharma PGIMS Rohtak